France Duodenal Ulcer Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Retail Pharmacies and Hospital Pharmacies), and France Duodenal Ulcer Treatment Market Insights, Industry Trend, Forecasts to 2035

France Duodenal Ulcer Treatment Market Size Insights Forecasts to 2035

• The France Duodenal Ulcer Treatment Market Size Was Estimated at USD 209.8 Million in 2024
• The France Duodenal Ulcer Treatment Market Size is Expected to Grow at a CAGR of Around 4.01% from 2025 to 2035
• The France Duodenal Ulcer Treatment Market Size is Expected to Reach USD 323.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, The France Duodenal Ulcer Treatment Market Size is Anticipated to Reach USD 323.3 Million by 2035, Growing at a CAGR of 4.01% from 2025 to 2035. The France duodenal ulcer treatment market is driven by the high prevalence of gastrointestinal disorders, increasing awareness and diagnosis of ulcers, greater use of advanced medications, improvements in healthcare infrastructure and access, and rising investment in research and development of more effective therapies.

Market Overview

The France Duodenal Ulcer Treatment Market Size includes medical products, therapies, and healthcare services that are used for diagnosis, treatment, and management of duodenal ulcers in France. Acid-suppressing drugs such as proton pump inhibitors (PPIs) and H2 receptor antagonists are a part of this market, which also comprises antibiotics for Helicobacter pylori eradication, antacids, and mucosal protective agents. Additionally, the market covers supportive treatments offered in hospitals, clinics, and pharmacies.

The duodenal ulcer treatment market in France is largely dependent on the health trends of the population and the prevalence of the disease. Helicobacter pylori infection, the leading cause of duodenal ulcer, is estimated to affect 20-30% of the people in France, and a substantial proportion of the infected individuals develop ulcer-related symptoms like abdominal pain, bleeding, and digestive discomfort. Further, factors such as the extensive use of NSAIDs, stress, related lifestyle patterns, and dietary habits are some of the contributors to ulcer incidence. These conditions prompt regular hospital visits, prescription of acid-reducing drugs and antibiotics, and clinical monitoring throughout the healthcare system in France.

The France Duodenal Ulcer Treatment Market Size has potential for growth facilitated by the developments in early diagnosis, increasing use of proton pump inhibitors, enhanced antibiotic combinations, and better management of drug resistance. Consequently, the aging population and the continued prevalence of H. pylori are the major contributors to the increased long-term treatment needs. The French government facilitates this market through national treatment guidelines issued by health authorities, wide reimbursement coverage, and public funding for gastrointestinal research and hospital care through national health budgets. These measures promote innovation, enhance treatment outcomes, and guarantee continued demand for effective duodenal ulcer therapies in France.

Report Coverage

This research report categorizes the market for the France Duodenal Ulcer Treatment Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France duodenal ulcer treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France duodenal ulcer treatment market.

Driving Factors

The France Duodenal Ulcer Treatment Market Size is driven by the widespread Helicobacter pylori infection cases, the increasing number of digestive disorders, and the aging population, which is more susceptible to ulcer complications. Besides these main factors, there are also more reasons for the market expansion, such as increased awareness and early diagnosis of the disease, the common and effective use of drugs like proton pump inhibitors and antibiotics, the presence of a well-developed healthcare system, and the availability of reimbursement that facilitates access to treatment.

Restraining Factors

The France Duodenal Ulcer Treatment Market Size is restrained by factors including the development of antibiotic resistance in H. pylori, which lowers treatment efficacy, the side effects of prolonged use of acid-reducing drugs, and delayed diagnosis in cases with mild symptoms or that are asymptomatic. Besides that, strict guidelines for treatment, measures for controlling costs, and a limited number of new drug classes beyond the existing ones can also act as growth barriers for the market.

Market Segmentation

The France duodenal ulcer treatment market share is classified into treatment, route of administration, and distribution channel.

• The proton pump inhibitors segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The France Duodenal Ulcer Treatment Market Size is segmented by treatment into proton pump inhibitors, H2 antagonists, antibiotics, and others. Among these, the proton pump inhibitors segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The proton pump inhibitors segment is growing because these drugs are highly effective at reducing stomach acid, healing duodenal ulcers faster, and preventing ulcer recurrence. They are widely prescribed in France as a first-line treatment for ulcers and H. pylori–related infections.

• The oral segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France Duodenal Ulcer Treatment Market Size is segmented by route of administration into oral and parenteral. Among these, the oral segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The oral segment is growing because most duodenal ulcer treatments, including proton pump inhibitors, H2 antagonists, and antibiotics, are easy to take as tablets or capsules, making them convenient, widely accessible, and suitable for both hospital and home use in France.

• The hospital pharmacies segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The France Duodenal Ulcer Treatment Market Size is segmented by distribution channel into retail pharmacies and hospital pharmacies. Among these, the hospital pharmacies segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospital pharmacies segment is growing because duodenal ulcer treatments are often prescribed and dispensed in hospitals, where patients receive professional guidance, diagnostic testing, and follow-up care, ensuring proper use of proton pump inhibitors, antibiotics, and other therapies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France Duodenal Ulcer Treatment Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GSK plc
• Pfizer Inc.
• Novartis AG
• Merck KGaA
• Abbott Laboratories
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Eisai Co., Ltd.
• Bristol-Myers Squibb Company
• NIHON GENERIC Co., Ltd.
• Sanofi S.A.
• Johnson & Johnson
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France Duodenal Ulcer Treatment Market Size based on the below-mentioned segments:

France Duodenal Ulcer Treatment Market, By Treatment

• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

France Duodenal Ulcer Treatment Market, By Route of Administration

• Oral
• Parenteral

France Duodenal Ulcer Treatment Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies